We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Urinary Biomarker Assessed for Diabetes Mellitus

By LabMedica International staff writers
Posted on 16 Oct 2013
Print article
Image: API 3000 Mass Spectrometer (Photo courtesy of Applied Biosystems).
Image: API 3000 Mass Spectrometer (Photo courtesy of Applied Biosystems).
Abnormal urinary excretion of a quaternary ammonium compound called betaine has been demonstrated in patients with diabetes or metabolic syndrome.

The main predictors of excretion of betaine in cardiovascular patients have been identified and an assessment made of its feasibility as a risk marker of future diabetes development.

Clinical scientists from the University of Bergen (Norway) collected from 2,396 patients urine and blood samples at baseline and in the majority at two visits during follow-up of a median of 39 months. Altogether, 1,772 patients provided urine at all three visits, 348 patients at two visits, and 276 only at baseline. Development of new diabetes during follow-up was assessed among 2,076 patients with no diagnosis of diabetes and either fasting glucose of less than 7.0 mmol/L or non-fasting glucose of less than 11.1 mmol/L at baseline.

Betaine in urine and plasma were measured by liquid-chromatography-tandem mass spectrometry at the laboratory of Bevital AS (Bergen, Norway). The median betaine excretion of 22.2 mmol/mol creatinine was more than three times higher in patients with diabetes compared with patients without diabetes, who showed a small but significant difference in excretion according to low 6.5 mmol/mol creatinine or high serum glucose of 7.1 mmol/mol creatinine. There was a distinct non-linear association between urinary betaine excretion and glycated hemoglobin, with a break point at 6.5%, and glycated hemoglobin was the strongest determinant of betaine excretion in patients with diabetes mellitus.

The authors conclude that diabetes mellitus and long-term glycemic control are the strongest determinants of urinary betaine excretion in a population of patients with mainly stable angina pectoris and without severe renal failure. The long-term test-retest stability is high and betaine excretion is also associated with an increased risk of new diabetes development. The study was published on August 6, 2013, in the journal Public Library of Science ONE.

Related Links:
University of Bergen
Bevital AS


Gold Member
C-Reactive Protein Reagent
CRP Ultra Wide Range Reagent Kit
Automated Blood Typing System
IH-500 NEXT
New
Anti-Secukinumab ELISA
LISA-TRACKER anti-Secukinumab
New
FLU/RSV Test
Humasis FLU/RSV Combo

Print article

Channels

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.